Dizal: Voluntary disclosure announcement on Schwarzer's first globally registered clinical study reaching a major research endpoint and oral report at the 2024 American Society of Clinical Oncology (ASCO) Conference
Dighe (Jiangsu) Pharmaceutical Co., Ltd. Investor Relations Activity Record Form from April to May 2024
Dizal: Voluntary disclosure announcement on Schwarzer's latest research results being selected for the 2024 American Society of Clinical Oncology (ASCO) Conference Report
Dizal: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Dizal: Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Digel Pharmaceutical Investor Relations Activity Record Table_2023 Pharmaceutical Special Group Performance Briefing
Dizal: 2023 Annual General Meeting of Shareholders Meeting Materials
Dizal: Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Performance Briefing
Dizal: Huatai United Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Dizal: Announcement on the completion of the plan to increase the shareholding of the company's directors and senior management and the results of increasing their holdings
Dizal: On promoting the 2024 “Improve Quality, Increase Efficiency, and Focus on Return” action plan
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Report and Verification Report on the Use of Funds Raised by Digee (Jiangsu) Pharmaceutical Co., Ltd. as of December 31, 2023
Dizal: 2023 Financial Statements and Audit Report
Dizal: Report on the use of previously raised funds
Dizal: Notice on convening the 2023 Annual General Meeting of Shareholders
Dizal: 2023 Annual Report Summary
Dizal: 2023 ANNUAL REPORT
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Special Report on the Capital Occupation by the Controlling Shareholders and Other Related Parties of Digee (Jiangsu) Pharmaceutical Co., Ltd. in 2023
Dizal: Announcement on Using Part of the Overraised Capital to Permanently Replenish Liquidity and Fund Raised Wealth Management Proceeds and Interest for Fund-raising Projects
Dizal: Huatai United Securities Co., Ltd.'s verification opinion on Dighe (Jiangsu) Pharmaceutical Co., Ltd.'s use of part of the overfunded capital to permanently supplement working capital and financial management income and interest
No Data